Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of JNJ-54175446 in MDD
NCT02902601Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing JNJ-54175446, Placebo + JNJ-54175446 and Placebo (3 arms). Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. Started Oct 2016; status: completed.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02902601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902601.